Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin

Information

  • Research Project
  • 8458109
  • ApplicationId
    8458109
  • Core Project Number
    R44DK088506
  • Full Project Number
    5R44DK088506-03
  • Serial Number
    088506
  • FOA Number
    PA-11-096
  • Sub Project Id
  • Project Start Date
    9/25/2010 - 14 years ago
  • Project End Date
    3/31/2015 - 9 years ago
  • Program Officer Name
    ARREAZA-RUBIN, GUILLERMO
  • Budget Start Date
    4/1/2013 - 11 years ago
  • Budget End Date
    3/31/2014 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    03
  • Suffix
  • Award Notice Date
    3/21/2013 - 11 years ago
Organizations

Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin

DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project (smart pumps). A proprietary approach is proposed based on the favorable physico-chemical properties conferred by chloro-aromatic substitutions in the insulin molecule. This Phase 2 SBIR application thus builds on progress obtain in the Phase 1 program in the characterization of 4-Cl-PheB24-KP-insulin. In this derivative of insulin lispro (the active component of Humalog; Eli Lilly and Co) the para proton of the aromatic ring of PheB24 is substituted by a larger and electronegative halogen atom. Results of Phase 1 studies established that this substitution (i) is compatible with native receptor-binding affinity and natie biological potency; (ii) leads to an accelerated rate of disassembly of the insulin hexamer in vitro; (iii) is associated with foreshortened pharmacodynamics of insulin action in euglycemic clamp studies in a pig model; and (iv) augments the resistance of insulin to physical degradation above room temperature on gentle agitation as in a pump reservoir. This unique confluence of advantageous features predicts significant clinical advantages both with respect to patient convenience and with respect to the performance of control algorithms employed in CGM-coupled closed-loop systems. Accordingly, a Phase 2 development plan is proposed in support of clinical-scale manufacture and optimization of formulation leading to I-GMP production (Aims 1-3) and formal toxicity/tolerance testing in animals in support of an IND application to the FDA (Aim 4). Achievement of these milestones will enable a future Phase 2B application in support of first-in-human trials, anticipated to be a phase 1a clamp study of healthy volunteers. The present application thus provides a logical bridge between highly promising in vitro and animal data, as generated in the Phase 1 SBIR program, and key pre-IND milestones.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    1474418
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:1474418\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    THERMALIN DIABETES, LLC
  • Organization Department
  • Organization DUNS
    963396747
  • Organization City
    CLEVELAND
  • Organization State
    OH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    441062119
  • Organization District
    UNITED STATES